Two stem cell specialists will soon become the latest to take their chances on the public markets: Cardio3 Biosciences and Cellular Dynamics have both announced plans for initial public offerings (IPOs).
Two stem cell specialists will soon become the latest to take their chances on the public markets: Cardio3 Biosciences and Cellular Dynamics have both announced plans for initial public offerings (IPOs).
Cellular Dynamics (based in Madison, Wisconsin) is hoping to raise up to $57.3m in its IPO on Nasdaq. The company,...
The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.
Swiss major confident that new oncology drugs will fill revenue gap.
Anselamimab was expected to complement Alexion's portfolio of amyloid therapies, but regulators will have to be convinced of its benefits to a patient subgroup in the CARES trial.
New US approval in heart failure with preserved or mildly reduced ejection fraction should add to Kerendia’s earning power on top of chronic kidney disease indication.
Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.
In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.
The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.
